25 June 2022 in Nature Communications
The SARS-CoV-2 Omicron variant is thought to cause less severe disease among the general population, but disease severity among at-risk populations is unknown. We performed a retrospective analysis using a matched cohort of United States veterans to compare the disease severity of subjects infected during Omicron and Delta predominant periods within 14 days of initial diagnosis. We identified 22,841 matched pairs for both periods. During the Omicron period, 20,681 (90.5%) veterans had mild, 1308 (5.7%) moderate, and 852 (3.7%) severe disease. During the Delta predominant period, 19,356 (84.7%) had mild, 1467 (6.4%) moderate, and 2018 (8.8%) severe disease. Moderate or severe disease was less likely during the Omicron period and more common among older subjects and those with more comorbidities. Here we show that infection with the Omicron variant is associated with less severe disease than the Delta variant in a high-risk older veteran population, and vaccinations provide protection against severe or critical disease.
1 April 2019 in Hospital Pediatrics
BACKGROUND AND OBJECTIVES: The decline in hospital mortality in children hospitalized with sepsis has increased the number of survivors. These survivors are at risk for adverse long-term outcomes, including readmission and recurrent or unresolved infections. We described the epidemiology of 90-day readmissions after sepsis hospitalization in children. We tested the hypothesis that a sepsis hospitalization increases odds of 90-day readmissions. METHODS: Retrospective cohort analysis of the Nationwide Readmissions Database. We included index unplanned admissions of non-neonatal pediatric patients and described the proportion of readmissions, including those involving infection or sepsis. We performed multivariable analysis to determine the odds of readmission after a sepsis and nonsepsis admission and compared costs of readmission after sepsis and nonsepsis admissions. RESULTS: Of 562 817 pediatric admissions, 7634 (1.4%) and 555 183 (98.6%) were discharged alive after admissions with and without sepsis. The rate of 90-day readmission after sepsis was 21.4%: 7.2% and 25.5% in previously healthy and chronically ill patients. The adjusted mean cost during readmission was $7385. Half of readmissions (52.9%) involved recurrent infection or sepsis. Sepsis admissions were associated with higher odds of readmission at 90 days compared with nonsepsis admissions (adjusted odds ratio 1.15, 95% confidence interval 1.08–1.23). The results remained unchanged for 30-day and 6-month readmissions. CONCLUSIONS: Readmissions occur after 1 in 5 pediatric sepsis hospitalizations and increase health care costs. Sepsis hospitalization increased odds of readmission and commonly involved recurrent infection or sepsis. Clinicians caring for these patients should consider surveillance for recurrent or unresolved infection, and researchers should explore underlying mechanisms and potential interventions to reduce readmissions.
14 June 2021 in Statistics in Medicine
22 April 2026 in Critical Care
NNNasrin Nikravangolsefid
RIRestrictive versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI) Study Investigators
Restrictive versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI) Study Investigators
+8
Observational studies link high net ultrafiltration (UFNET) rates during continuous kidney replacement therapy (CKRT) to increased mortality. The Restricti
13 October 2025 in Critical Care Explorations
OBJECTIVES: Sepsis trials likely include patients who vary in response to therapeutic interventions. The optimal approach to identify such differences in treatment response remains unclear. Estimating individualized absolute risk differences (iARDs) to model treatment response at an individual patient level using supervised effect models applied to randomized trial data may be informative. We explored the relationship between two subgrouping approaches and a recently published iARD model for the effect of early goal-directed therapy (EGDT) resuscitation in sepsis. DESIGN: Secondary analysis of the Protocolized Care for Early Septic Shock (ProCESS) and Australasian Resuscitation in Sepsis Evaluation (ARISE) trials. We applied clinical subtypes (α, β, γ, δ) to 829 ProCESS and 1588 ARISE patients and biologic “hyperinflammatory” and “nonhyperinflammatory” subphenotypes to 363 ProCESS patients with biomarker data using established methods. We predicted iARDs with supervised learning using clinical variables as predictors and 90-day mortality as the primary outcome. We evaluated iARD variability within subgroups. SETTING: Eighty-one sites worldwide. PATIENTS/SUBJECTS: Adults with septic shock. INTERVENTIONS: EGDT or usual care. MEASUREMENTS AND MAIN RESULTS: The average treatment effect of EGDT appeared to vary within both clinical and biologic subphenotypes. EGDT appeared potentially beneficial in the β and nonhyperinflammatory subphenotypes but harmful in the γ and hyperinflammatory subphenotypes. However, the predicted iARDs within each subgroup ranged from considerable harm to considerable benefit. For example, for the β-subtype, the average mortality reduction from EGDT was 8.5% (95% CI, –0.4 to 17.5), but the iARDs ranged from a 29% increase to a 16% reduction in mortality, with 39% of patients predicted to be harmed. CONCLUSIONS: Although both clinical and biologic phenotyping may identify subgroups whose average treatment effect is beneficial or harmful, individual risks and benefits within subgroups still vary dramatically, raising concern that phenotyping may not reliably or safely personalize sepsis care.
19 June 2025 in Contemporary Clinical Trials Communications
The months following hospitalization for sepsis and lower respiratory tract infection can often be very difficult for patients. Many will have subsequent clinical deterioration, which for some requires hospital readmission while, for others, transition to hospice care may be more appropriate. Unfortunately, there is a lack of high-quality evidence regarding how best to support patients in this period. Remote patient monitoring (RPM) technology can allow patients to remain at home yet be monitored for early signs of clinical deterioration. However, what should be monitored, and how any response should be coordinated, is unclear. We designed a pragmatic adaptive randomized clinical trial to determine the effect of four post-discharge RPM strategies comprising low vs. high intensity monitoring and standard versus enhanced care team response on 90-day hospital readmission rates. Adults admitted to the hospital with sepsis or lower respiratory tract infection (index admission) are recruited and randomized to usual care (structured telephonic support [STS]) or one of four post-discharge RPM care models in addition to STS. The primary outcome is home days, a composite endpoint of 90-day mortality and the number of days a patient spends at home within 90 days after discharge to home from the index admission. Hospital readmissions will be measured primarily by health insurance claims data. Secondary endpoints, such as functional status and health-related quality of life, will be measured at baseline and 90 days. An adaptive randomization process is run quarterly, improving patients' chances to be randomized to the highest-performing intervention arms. The study evaluates different post-discharge monitoring and workforce strategies to increase home days. With a large, representative sample and pragmatic adaptive study design, this research aims to deliver key insights into effective remote discharge monitoring technology and workforce deployment, benefiting patients, providers, and payers. This trial is registered at clinicaltrials.gov (NCT04829188). https://clinicaltrials.gov/study/NCT04829188. Date of registration: January 4, 2021.